News
Eli Lilly shares dropped Thursday as Novo Nordisk notched a coverage win for its obesity drug, a sign of the competition in ...
Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...
Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...
In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as ...
Novo Nordisk A/S shares gained on expectations that competition for its blockbuster obesity shot Wegovy will subside later ...
Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs ...
LONDON/COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results